- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05743894
RDN Fesibility Study
February 15, 2023 updated by: Gormin Tan, Chinese University of Hong Kong
Renal Nerve Simulation Guided Renal Sympathetic Denervation With Siymplicity Spyral Radiofrequency Catheter for Resistant Hypertension: a Feasibility Study.
Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled.
The RDN works mainly by selectively disabling the nerves around the renal arteries and reducing blood pressure increase.
However, despite the early success showed in the SYMPLICITY HTN-2 trial, the SYMPLICITY HTN-3 trial failed to demonstrate a significant BP reduction when compared to sham-control.
incomplete disabling might result in inadequate denervation and were cited as some of the contributors to the nil result in the SYMPLICITY HTN-3 .
The new generation of the Symplicity Spyral catheter aims to address some of these issues by altering the configuration of the catheter to allow better apposition to the renal arterial wall and increasing the numbers of electrodes to faciiitate more thorough ablations.
However, the adequacy of sympathetic denervation with this new catheter can not be easily assessed at the time of the procedure as there is no simple physiological or biochemical feedbacks that can be monitored during the procedure.
Blood pressure response by renal nerve simulation (RNS) during RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the efficacy during the procedure and predict the BP response 6 months after RDN.
The feasibility of RNS guided RDN procedure using the new generation of Symplicity Spyral catheter has not been reported.
We therefore aim to explore the feasibility of RNS guided RDN with Symplicity Spyral Radiofrequency Catheter in patient with resistant hypertension.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled.
The RDN works mainly by selectively disabling the nerves around the renal arteries and reducing blood pressure increase.
However, despite the early success showed in the SYMPLICITY HTN-2 trial, the SYMPLICITY HTN-3 trial failed to demonstrate a significant BP reduction when compared to sham-control.
incomplete disabling might result in inadequate denervation and were cited as some of the contributors to the nil result in the SYMPLICITY HTN-3 .
The new generation of the Symplicity Spyral catheter aims to address some of these issues by altering the configuration of the catheter to allow better apposition to the renal arterial wall and increasing the numbers of electrodes to faciiitate more thorough ablations.
However, the adequacy of sympathetic denervation with this new catheter can not be easily assessed at the time of the procedure as there is no simple physiological or biochemical feedbacks that can be monitored during the procedure.
Blood pressure response by renal nerve simulation (RNS) during RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the efficacy during the procedure and predict the BP response 6 months after RDN.
The feasibility of RNS guided RDN procedure using the new generation of Symplicity Spyral catheter has not been reported.
We therefore aim to explore the feasibility of RNS guided RDN with Symplicity Spyral Radiofrequency Catheter in patient with resistant hypertension.
Study Type
Observational
Enrollment (Anticipated)
10
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shatin
-
Hong Kong, Shatin, Hong Kong, 0000
- Recruiting
- Prince of Wales Hospital
-
Contact:
- Daniel Xu
- Phone Number: 1518 35051518
- Email: danielxu@cuhk.edu.hk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This is a feasibility study, small sample size serves as a proof of concept
Description
Inclusion Criteria:
- Age > 18 years
- With resistant hypertension as defined by systolic BP over 140 mmHg on 24 hours ambulatory blood pressure measurement (ABPM)
- Already on a stable dose of at least 3 anti-hypertensive drugs of different classes for 3 months.
- subject is recruited for Transcatheter Renal Denervation
Exclusion Criteria:
- Individual has undergone prior renal denervation.
- Presence of renal artery stenosis >50%.
- Main renal artery diameter <3mm and larger than 8mm by visual assessment on angiography.
- Previous renal stenting.
- Subject with Estimated GFR <30ml/min/1.73m2 as calculated using the MDRD formula.
- Subject with renal transplant, single kidney, active nephritis or polycystic kidney disease.
- Subject with known pheochromocytoma, Cushing's Syndrome (hypercortisolism), primary hyperaldosteronism, coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or primary hyperparathyroidism.
- Subject with unstable cardiac conditions such as myocardial infarction, unstable angina, malignant arrythmia, pulmonary embolism, significant valvular condition awaiting surgery or recent cerebrovascular accident within 3 months of recruitment.
- Subject who is pregnant or planning for pregnancy during the study duration.
- Subject who is enrolled in another device study for renal sympathetic denervation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the difference of RNS BP response before and after RDN
Time Frame: 24-hrs
|
24-hrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the changes in 24-hour ABPM after RDN
Time Frame: 6 months
|
6 months
|
the change in office BP measurement;
Time Frame: 6 months
|
6 months
|
the change in the number and dosage of anti-hypertensives
Time Frame: 6 months
|
6 months
|
the change in renal function as measured by estimated GFR
Time Frame: 6 months
|
6 months
|
the change in renal function as measured by ratio urine albumin-creatinine
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tam GM, Yan BP, Shetty SV, Lam YY. Transcatheter renal artery sympathetic denervation for resistant hypertension: an old paradigm revisited. Int J Cardiol. 2013 Apr 15;164(3):277-81. doi: 10.1016/j.ijcard.2012.01.048. Epub 2012 Feb 14.
- Schmieder RE, Mahfoud F, Mancia G, Azizi M, Bohm M, Dimitriadis K, Kario K, Kroon AA, D Lobo M, Ott C, Pathak A, Persu A, Scalise F, Schlaich M, Kreutz R, Tsioufis C; members of the ESH Working Group on Device-Based Treatment of Hypertension. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021 Sep 1;39(9):1733-1741. doi: 10.1097/HJH.0000000000002933.
- Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, Kario K, Bohm M, Sharp ASP, Davies JE, Osborn JW, Fink GD, Euler DE, Cohen DL, Schlaich MP, Esler MD. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. JACC Cardiovasc Interv. 2019 Jun 24;12(12):1095-1105. doi: 10.1016/j.jcin.2019.02.050.
- Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 Dec 4;376(9756):1903-9. doi: 10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17.
- Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.
- Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21;36(4):219-27. doi: 10.1093/eurheartj/ehu441. Epub 2014 Nov 16.
- Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Bohm M; SPYRAL HTN-OFF MED trial investigators*. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017 Nov 11;390(10108):2160-2170. doi: 10.1016/S0140-6736(17)32281-X. Epub 2017 Aug 28.
- Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K; SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-2355. doi: 10.1016/S0140-6736(18)30951-6. Epub 2018 May 23.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2022
Primary Completion (Anticipated)
April 1, 2023
Study Completion (Anticipated)
July 1, 2023
Study Registration Dates
First Submitted
February 2, 2023
First Submitted That Met QC Criteria
February 15, 2023
First Posted (Actual)
February 24, 2023
Study Record Updates
Last Update Posted (Actual)
February 24, 2023
Last Update Submitted That Met QC Criteria
February 15, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022.391
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension, Renal
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and other collaboratorsRecruitingHeart Failure | Percutaneous Transluminal Angioplasty | Renovascular Hypertension | Renal Artery Stenosis Atherosclerotic | Renovascular Hypertension With Renal FailureDenmark
-
Erasme University HospitalUnknownRenal Function | Resistant Hypertension | Ambulatory Blood Pressure | Renal DenervationBelgium
-
Peking University First HospitalRecruitingRenal Artery Stenosis Atherosclerotic | Secondary Hypertension Renal ArterialChina
-
Mayo ClinicUniversity of Alabama at Birmingham; University of Mississippi Medical CenterCompletedChronic Kidney Disease | Renal Artery Stenosis | Ischemic Nephropathy | Renovascular DiseaseUnited States
-
Universita di VeronaUnknownRenal Artery Obstruction | Renovascular HypertensionItaly
-
Novartis PharmaceuticalsCompletedHypertension With Renal DysfunctionJapan
-
Peking Union Medical College HospitalNot yet recruitingDrug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis--a Multicenter StudyHypertension, Renovascular
-
Mayo ClinicCompletedAtherosclerotic Renal Artery Stenosis | Ischemic Nephropathy | Renovascular HypertensionUnited States
-
Daiichi Sankyo Co., Ltd.CompletedHypertension With Moderate Renal ImpairmentJapan
-
Medtronic EndovascularWithdrawnResistant Hypertension | Uncontrolled Hypertension | Renal Artery AblationItaly
Clinical Trials on Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter
-
Medtronic VascularRecruitingCardiovascular Diseases | Vascular Diseases | Hypertension | Diabetes Mellitus | Chronic Kidney DiseasesUnited States, Monaco, Australia, Germany, France, United Kingdom, Belgium, Netherlands, Sweden, Greece
-
Medtronic VascularCompletedCardiovascular Diseases | Vascular Diseases | HypertensionUnited States, United Kingdom, Germany, Greece
-
Medtronic VascularCompletedHypertension | Atrial FibrillationUnited States, Germany
-
Chinese University of Hong KongRecruitingHypertension, RenalHong Kong
-
Medtronic VascularActive, not recruitingCardiovascular Diseases | Vascular Diseases | HypertensionUnited States, Germany, Canada, Australia, United Kingdom, France, Ireland, Japan, Austria, Greece
-
Saskatchewan Health Authority - Regina AreaUniversity of SaskatchewanActive, not recruitingLoin Pain-Hematuria SyndromeCanada
-
University Hospital, SaarlandWithdrawnChronic Heart Failure | Cardio-Renal SyndromeAustria, Germany, Switzerland, Sweden
-
Adolfo FontenlaRecruiting
-
Pamela Youde Nethersole Eastern HospitalTerminatedDiabetes Mellitus | Hypertension, Resistant | Renal Denervation TherapyHong Kong
-
Dr. Harindra WijeysunderaMedtronic; Mars Excellence in Clinical Innovation and Technology EvaluationTerminatedTreatment-Resistant HypertensionCanada